Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05669755 · ClinicalTrials.gov registry record · Phase 3
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels
A Phase 3 study of Cardiovascular Disease, sponsored by Novo Nordisk A/S.
- Active
- Registry status
- Phase 3
- Development phase
- 7,101
- Enrollment target
- 20
- Study locations
NCT05669755 is a Phase 3 study of Cardiovascular Disease that is active but no longer recruiting, run by Novo Nordisk A/S. The registered enrollment target is 7,101 participants, above the 2,661-participant average among 136 other Cardiovascular Disease trials with a reported enrollment target (167% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT05669755, a Phase 3 study of Cardiovascular Disease, is active but no longer recruiting, sponsored by Novo Nordisk A/S.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 7,101 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will look at the effects of CagriSema on cardiovascular events (for example heart attack and stroke) in people living with cardiovascular disease. Participants will either get CagriSema or a dummy medicine (also called "placebo") which has no effect on the body. Which treatment participants will get will be decided by chance. Participant's chance of getting CagriSema or placebo is the same. Participants will inject the study medicine once a week. The study medicine will be injected briefly with a thin needle, typically in the stomach, thighs or upper arms. The study will last for up to 4.5 years.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Semaglutide
- DRUG Cagrilintide
Study Locations (20)
California
- National Heart Institute Cal - Beverly Hills
- Valley Clinical Trials - Covina
- Scripps Wht Diab Inst La Jolla - La Jolla
- First Valley Medical Group - Lancaster
- Clinical Trials Research_Sacramento - Lincoln
- Torrance Clin Res Inst, Inc. - Lomita
- Pacific Clinical Studies - Los Alamitos
- Monterey Endocrine & Diabetes Institute, Inc - Monterey
- Valley Clinical Trials, Inc. - Northridge
- Desert Oasis Hlthcr Med Group - Palm Springs
- Western University of Health Sciences - Pomona
- Linda Vista Health Care Ctr - San Diego
- N America Res Inst - San Dimas - San Dimas
- Encompass Clinical Research_Spring Valley - Spring Valley
- Lundquist Inst.-Biom Inno-UCLA - Torrance
Alabama
- Univ of Alabama Birmingham - Birmingham
- Chambliss Clinical Trials LLC - Montgomery
Arizona
- Honor Health - Scottsdale
Connecticut
- Bridgeport Hospital - Bridgeport
Florida
- Innovative Research of W FL - Clearwater
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,101 participants |
| Start Date | 2023-03-01 |
| Est. Completion | 2027-10-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05669755
The ClinicalTrials.gov registry entry for NCT05669755 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 7,101 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,661-participant average among 136 other Cardiovascular Disease trials with a reported enrollment target (167% higher). The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cardiovascular Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05669755 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT05669755 about?
NCT05669755 is a clinical study titled "REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels". This study will look at the effects of CagriSema on cardiovascular events (for example heart attack and stroke) in people living with cardiovascular disease. Participants will either get CagriSema or a dummy medicine (also called "placebo") which has no effect on the body. Which treatment participan...
What is the current status of trial NCT05669755?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 7,101 participants. The study started on 2023-03-01. Estimated completion is 2027-10-13.
What conditions does trial NCT05669755 study?
This clinical trial studies the following conditions: Cardiovascular Disease.
What interventions are being tested in trial NCT05669755?
The interventions under investigation include: Placebo (DRUG), Semaglutide (DRUG), Cagrilintide (DRUG).
Who is sponsoring clinical trial NCT05669755?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05669755 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
RECRUITING · Phase 3
-
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
RECRUITING · Phase 3
-
VITAL Rhythm Study
ACTIVE NOT RECRUITING · Phase 3
-
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event
ACTIVE NOT RECRUITING · Phase 3
-
Vitamin D and Omega-3 Trial (VITAL)
ACTIVE NOT RECRUITING · Phase 3
-
Effect of a Decision Aid About Statin Use in Patients With Type 2 Diabetes Mellitus
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.